|
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Treatment of Psoriasis Using Acitretin in HIV-Positive Patients conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Treatment of Psoriasis Using Acitretin in HIV-Positive Patients Clinical research trials and Treatment of Psoriasis Using Acitretin in HIV-Positive Patients health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Treatment of Psoriasis Using Acitretin in HIV-Positive Patients. Treatment of Psoriasis Using Acitretin in HIV-Positive Patients Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Treatment of Psoriasis Using Acitretin in HIV-Positive Patients clinical trial. Subjects frequently get the best healthcare possible for their Treatment of Psoriasis Using Acitretin in HIV-Positive Patients condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Treatment of Psoriasis Using Acitretin in HIV-Positive Patients  Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
For Condition: HIV Infections,Psoriasis
Status: Completed
Sponsor(s): Hoffmann-La Roche ,
Synopsis: To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients. Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients.
Details: Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients. Patients receive acitretin daily, with dose increases every 4 weeks based on quantitative assessment of the skin using the Psoriasis Area and Severity Index (PASI). Treatment continues for a total of 20 weeks. Patients are followed every 2 weeks.
Eligibility:
Study Type: Interventional, Treatment, Placebo Control, Efficacy Study
Minimum Age/Maximum Age: 18 Years/55 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Any nondermatologic medication. Patients must have: - HIV infection. - Psoriasis involving at least 10 percent of body surface.
Total Enrollment: 30
Location and Contact Information:
Beth Israel Med Ctr
New York City, New York, 10003
United States
Additional Information:
Study ID Numbers: 239A; 65-93(2)
Study Start Date:
Record last reviewed: April 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002143
Other Hiv Infections Studies:
1. Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis
2. Micellar Paclitaxel to Treat Severe Psoriasis
3. Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
4. Etanercept (Enbrel®) in Psoriasis - Pediatrics
5. A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis
Related Studies:
Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
|
|
|
|
|
|
|
|
